CM
CYTK icon

Cornerstone Management’s Cytokinetics CYTK Stock Holding History

Cornerstone Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-50
Closed -$1.76K – 97
2023
Q1 		$1.76K Hold
50
– – ﹤0.01% 212
2022
Q4 		$2.29K Hold
50
– – ﹤0.01% 196
2022
Q3 		$2.42K Hold
50
– – ﹤0.01% 202
2022
Q2 		$1.97K Hold
50
– – ﹤0.01% 213
2022
Q1 		$1.84K Hold
50
– – ﹤0.01% 220
2021
Q4 		$2.28K Buy
+50
New +$1.93K ﹤0.01% 194

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Cornerstone Management's CYTK Position: Q2 2023 in Review

Cornerstone Management sold out of Cytokinetics (CYTK) in Q2 2023, closing a stake of 50 shares — an estimated $1.76K sold.

Cornerstone Management first reported a position in CYTK in Q4 2021 and held it in 6 quarters. The position peaked at $2.42K in Q3 2022. 253 funds tracked by Wall St. Rank hold CYTK as of Q2 2023.

  • Cornerstone Management reported no remaining Cytokinetics position as of Q2 2023 after selling out during the quarter.
  • Cornerstone Management sold 50 Cytokinetics shares in Q2 2023, an estimated $1.76K.
  • Cornerstone Management first reported a position in Cytokinetics in Q4 2021 and held it in 6 quarters.
  • Cornerstone Management's Cytokinetics position peaked at $2.42K in Q3 2022.
  • 253 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2023.

Based on Cornerstone Management's 13F filing for Q2 2023, filed 10 Aug 2023.